FDA approves Ilumya for adults with psoriatic arthritis

Coverage, in order

1. 12d ago
   
   Healio indie randomized trial

   FDA approves Ilumya for adults with psoriatic arthritis

   The interleukin-23 inhibitor tildrakizumab-asmn has received FDA approval for adults with active psoriatic arthritis, according to a press release from the manufacturer. The approval follows the global, multicenter, randomized, double-blind, placebo-controlled INSPIRE-1 and INSPIRE-2 phase 3…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.